RxDoctor Payments Data

Beau Jennings, DO

Family Medicine · Broken Arrow, OKNPI 1275568115

Payments from drug & device makers

$9,400in general payments, 2019–2025

Across 597 payments — averaging $15.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$949
  • GSK$824
  • AstraZeneca$722
  • Pfizer$697
  • Bayer$604
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$9,400100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,400 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$81,046
Medicare patients
223
Services billed
4,853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin123$115,948
EliquisApixaban128$109,961
MounjaroTirzepatide47$48,220
RybelsusSemaglutide33$46,721
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$45,298
OzempicSemaglutide36$35,340
Tresiba Flextouch U-200Insulin Degludec23$29,005
MyrbetriqMirabegron22$21,379
Breo ElliptaFluticasone/Vilanterol28$20,568
XareltoRivaroxaban20$18,447
Janumet XrSitagliptin Phos/Metformin Hcl22$16,952
Tresiba Flextouch U-100Insulin Degludec17$16,948
SymbicortBudesonide/Formoterol Fumarate35$12,110
JanuviaSitagliptin Phosphate11$12,005
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$11,353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$86$115,948123 claims
PfizerEliquis$697$109,961128 claims
Novo NordiskRybelsus, Ozempic$1,735$82,06169 claims
GSKTrelegy Ellipta, Breo Ellipta$824$65,86684 claims
Lilly USA, LLCMounjaro$949$48,22047 claims
MerckJanumet Xr, Januvia, Belsomra$362$37,31652 claims
AstraZenecaSymbicort, Farxiga$722$21,54351 claims
Astellas Pharma US IncMyrbetriq$276$21,37922 claims
Johnson & JohnsonXarelto$189$18,44720 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$2,045235 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Broken Arrow

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →